Loperamide and Eluxadoline Interaction
Drug interaction information between Loperamide and Eluxadoline.
Loperamide and Eluxadoline have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Loperamide and Eluxadoline. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
These medicines both work to slow down your bowels, and using them together can cause dangerous levels of constipation.
What To Do
Do not use loperamide long-term with this drug, and stop it immediately if you become constipated.
FDA Label Information
Examples: cyclosporine, gemfibrozil, antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag Drugs that Cause Constipation Clinical Impact: Increased risk for constipation related adverse reactions and potential for constipation related serious adverse reactions Intervention: Avoid use with other drugs that may cause constipation (see below); loperamide may be used occasionally for acute management of severe diarrhea but avoid chronic use. Discontinue loperamide immediately if constipation occurs.
Eluxadoline Also Interacts With
- Rosuvastatin moderate
- Rifampin moderate
- Gemfibrozil moderate
- Cyclosporine minor
- Alosetron minor
Frequently Asked Questions
Can I take Loperamide and Eluxadoline together?
This is a moderate interaction. Do not use loperamide long-term with this drug, and stop it immediately if you become constipated.
How serious is the interaction between Loperamide and Eluxadoline?
This interaction is classified as "moderate" severity by the FDA. Moderate interactions may worsen your condition or change how your medications work.
Why do Loperamide and Eluxadoline interact?
These medicines both work to slow down your bowels, and using them together can cause dangerous levels of constipation.
Understanding the Loperamide and Eluxadoline Interaction
FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Loperamide belongs to the Antidiarrheal (Opioid Receptor Agonist) class and Eluxadoline belongs to the Mu-Opioid Receptor Agonist (IBS-D) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: These medicines both work to slow down your bowels, and using them together can cause dangerous levels of constipation. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Loperamide has 2 total documented interactions on file in this dataset, and Eluxadoline has 6. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Do not use loperamide long-term with this drug, and stop it immediately if you become constipated. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Loperamide or Eluxadoline based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.